FocaL Mass Drug Administration for Vivax Malaria Elimination (FLAME): a Pragmatic Cluster Randomized Controlled Trial in Peru
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 7,530
- 试验地点
- 2
- 主要终点
- Cumulative Incidence of Plasmodium vivax infections
研究概览
简要总结
FLAME is an open-label cluster-randomized controlled trial that aims to determine the effectiveness of focal mass drug administration (fMDA) to reduce the incidence of Plasmodium vivax malaria in the Loreto Department in Peru. Standard interventions, including symptomatic and asymptomatic screening for malaria infections, provision of insecticide-treated bednets, and environmental transmission monitoring, will be compared to clusters of villages randomized to receive anti-malarial drugs.
详细描述
This trial is an open-label cluster-randomized controlled trial in Loreto Region, Peru, a low transmission setting (i.e. anual incidence <250/1000), where the unit of randomization is a village, or cluster. There will be two study arms: Control and fMDA. Villages will receive fMDA or control based on a restricted randomization that includes baseline factors such as incidence, distance to a health post, and population.
The interventions for both control and fMDA clusters will include standard interventions (high coverage of vector control, passive and active symptomatic case management, and RACD of asymptomatic cases). The intervention will take place in 2 rounds for three cycles, each cycle separated by regular intervals. fMDA will target high-risk villagers (individuals residing in households that are within 200 meters of a Pv index case households from the prior 2 years). High-risk status will be determined in each survey before the administration of Round "a" of fMDA. Pv index cases refers to confirmed Pv cases reported by the health system.
In each cycle of fMDA, the 1st round will include 3 days of chloroquine (CQ) for treatment of Pv asexual blood stages, with TQ for Pv liver stages. With a prolonged half-life up to 15 days and post-treatment effect observed up to 77 days. TQ will also have a prophylactic and likely gametocytocidal effect for Pv and Pf. For continued anti-relapse, prophylactic, and transmission-blocking effects, a follow-up round will include TQ with single-dose CQ (sdCQ). If TQ, but not PQ, is contraindicated, a standard 7-day PQ course will be used. CQ, including in a single dose, will potentiate the anti-relapse effect of PQ, and likely TQ. Preliminary data from the study area shows that 32% of the study population is <16 years old and will receive PQ. However, the investigators do not anticipate this to influence the impact of the fMDA due to our use of directly observed therapy (DOT). If pediatric TQ is approved for use in Peru during the study, an addendum to the protocol will be presented for approval by the IRB and INS and incorporated into the study.
An endline survey will be carried out at the end of the 3-year trial intervention period. An interim survey will also be conducted in the entirety of the population both arms. In each of these surveys, a dried blood spot will be collected from all participants. Anyone with fever in the prior 48 hours and a positive blood smear from a local health post will receive treatment per national policy. Anyone with fever in the prior 48 hours without a positive blood smear will be encouraged to go to a health post. To maximize public health relevance, the trial will be pragmatic and implemented through the existing health system.
The primary research objectives are:
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Cluster eligibility
- •Within 8 hours transport of Iquitos
- •Incidence <250/1000 and >2 cases year prior to trial
- •Population size (<650)
- •Chloroquine (CQ) eligibility
- •Resides in neighboring household but within 200 m of Pv index case in the past 2 years
- •Age ≥6 months old
- •Present for intervention
- •Adult ≥18 years old that provides informed consent
- •A child ≥8 years and <18 years old that provides informed assent and has informed consent from their parents
- •A child ≥6 months old and <8 years old that has informed consent from their parents
- •Tafenoquine (TQ) eligibility
- •Eligible to receive CQ
- •Age ≥16 years old
- •Adult ≥18 years old that provides informed consent
- •A child ≥16 years and <18 years old that provides informed assent and has informed consent from their parents
- •Primaquine eligibility
- •Eligible to receive CQ and ineligible to receive TQ
- •Age ≥6 months old
- •Adult ≥18 years old that provides informed consent
- •A child ≥8 years and <18 years old that provides informed assent and has informed consent from their parents
- •A child ≥6 months old and <8 years old that has informed consent from their parents
- •Baseline evaluation and informed consent
- •Villagers will be eligible to participate in surveys if they slept in a household in cluster randomized to control or focal mass drug administration (fMDA) for at least one night in the past four weeks
- •Eligibility for fMDA
- •High-risk villagers are defined as individuals residing in households that are within 200 meters of a Plasmodium vivax index case households from the prior 2 years (including individuals in the index case household) will be eligible to receive fMDA that cycle
- •Villagers that were eligible but missed in the 1st round in a cycle, or become eligible in the next two months, will not be eligible to receive fMDA in the 2nd round in a cycle.
排除标准
- •Chloroquine eligibility
- •History of retinal or visual field changes
- •Known hypersensitivity or adverse reaction to CQ
- •Currently taking CQ or have taken CQ in the past four weeks
- •Ineligible for TQ or PQ (see criteria below)
- •Hemoglobin <9 g/dL
- •Tafenoquine eligibility
- •G6PD deficiency or intermediate status (defined as activity ≤6.0 UI/gHb per SD biosensor)
- •G6PD status unknown or refusal of G6PD status test
- •Acute or severe malaria
- •Pregnancy (known or identified by pregnancy test)
- •Refusal of pregnancy test if new amenorrhea in the past 4 weeks
- •Woman breastfeeding a child that is G6PD deficient or with unknown G6PD status
- •Known hypersensitivity or adverse reaction to TQ or PQ
- •Have taken mefloquine (i.e. artesunate- mefloquine), TQ or PQ, or other antimalarial in the past four weeks
- •Hemoglobin < 9 g/dL
- •Primaquine eligibility
- •G6PD deficiency (defined as activity ≤4.0 UI/gHb per SD biosensor)
- •G6PD status unknown or refusal of G6PD status test
- •Acute or severe malaria
- •Pregnancy (known or identified by pregnancy test)
- •Refusal of pregnancy test if new amenorrhea in the past 4 weeks
- •Breastfeeding child with documented or unknown G6PD deficiency status
- •Woman breastfeeding a child with documented or unknown G6PD deficiency status
- •Known hypersensitivity or adverse reaction to TQ or PQ
- •Have taken mefloquine (i.e. artesunate- mefloquine), TQ or PQ, or other antimalarial in the past four weeks
- •Hemoglobin < 9 g/dL
研究组 & 干预措施
Focal Mass Drug Administration (fMDA)
Standard interventions in addition to focal mass drug administration. Focal mass drug administration will include using primaquine, chloroquine, and tafenoquine, for high-risk individuals residing in households that are within 200 meters of a Plasmodium vivax (Pv) index case households from the prior 2 years (including individuals in the index case household). Pv index cases include symptomatic cases detected at health facilities or in fever screenings, and asymptomatic cases identified during routine active case detection by health facilities. Households will then be notified regarding their potential to receive two rounds fMDA that cycle. Eligibility to receive medications as part of fMDA will be assessed prior to each administration and include glucose 6 phosphate dehydrogenase (G6PD) testing and counseling if not previously conducted or result is not available on the participant's identification card.
干预措施: Focal Mass Drug Administration (fMDA) (Drug)
结局指标
主要结局
Cumulative Incidence of Plasmodium vivax infections
时间窗: From enrollment through study completion, over 36-month follow-up study period
Number of microscopy-confirmed, Plasmodium vivax malaria cases in residents reported from health facilities per population over the 36-month follow-up study period
次要结局
- Cost per disability life year (DALY)(From enrollment through study completion, over 4 years)
- Genetic diversity of Plasmodium vivax(From enrollment through study completion, over 4 trial years)
- Tolerability of study drugs(Over drug administration period, unique for each study drug (7 days for CQ/PQ regimens and 3 days for CQ/TQ regimens))
- Adherence to study drugs(Unique for each patient based on drug regimen (7 days for CQ/PQ regimens and 3 days for CQ/TQ regimens))
- Refusal rates(During each fMDA round, twice per year for 3 consecutive years)
- Cost per incident case averted(From enrollment through study completion, over 4 years)
- Prevalence of Plasmodium vivax infection(At endline survey in trial year 4, 3 years after enrollment in study in trial year 1)
- Plasmodium vivax seroprevalence(At endline survey in trial year 4, 3 years after enrollment in study in trial year 1)
- Program costs per unit fMDA round(From enrollment through study completion, over 4 years)
- Cost per economic dollar due to malaria saved(From enrollment through study completion, over 4 years)
- Program costs per unit(From enrollment through study completion, over 4 years)